NXSCF Company Profile and Key Details

Q: Who are the executives of NXSCF?

Mr. Jon SwansonChief Operating OfficerMs. Judith Mitchell M.B.A.MD, Chief Executive Officer & Executive DirectorMr. Michael MorelloVice President of SalesDr. Matthew Franco MynttiFounder & Chief Technology OfficerMs. Jacqueline Butler CA (ICAEW)Chief Financial OfficerMs. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICDCompany Sec.Mr. Martyn JacobsHead of Investor Relations

PNK : NXSCF

Next Science

$0.18

-0.0003-0.18%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Next Science Limited (NXSCF) stock declined over -90.00%, trading at $0.01 on OTC, down from the previous close of $0.10. The stock opened at $0.06, fluctuating between $0.01 and $0.06 in the recent session.

Stock Snapshot

0.1

Prev. Close

2.93M

Market Cap

0.01

Day Low

-0.33

P/E Ratio

-0.03

EPS (TTM)

-0.09

Cash Flow per Share

0.06

Open

292.63M

Number of Shares

0.06

Day High

48.57%

Free Float in %

0.05

Book Value

40K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 03, 2026	0.06	0.06	0.01	0.01	80K
Dec 30, 2025	0.05	0.05	0.05	0.05	20K
Dec 29, 2025	0.08	0.08	0.08	0.08	993
Dec 26, 2025	0.06	0.06	0.06	0.06	2K
Dec 24, 2025	0.06	0.06	0.06	0.06	7.6K
Dec 08, 2025	0.08	0.08	0.08	0.08	59.98K
Dec 02, 2025	0.08	0.08	0.08	0.08	1K
Nov 12, 2025	0.09	0.09	0.09	0.09	100
Nov 07, 2025	0.06	0.11	0.06	0.11	23.11K
Oct 30, 2025	0.06	0.06	0.06	0.06	2.5K
Oct 16, 2025	0.06	0.06	0.06	0.06	15K
Oct 03, 2025	0.10	0.10	0.10	0.10	25K
Sep 30, 2025	0.08	0.08	0.08	0.08	250
Sep 24, 2025	0.06	0.06	0.06	0.06	150
Sep 19, 2025	0.08	0.08	0.08	0.08	4K
Sep 18, 2025	0.10	0.10	0.10	0.10	700
Sep 16, 2025	0.08	0.08	0.08	0.08	50K
Sep 15, 2025	0.06	0.06	0.06	0.06	22.09K
Sep 11, 2025	0.06	0.06	0.06	0.06	0
Sep 08, 2025	0.06	0.06	0.06	0.06	0

Contact Details

Sydney, NSW 2067

Australia

https://www.nextscience.com 612 860 75126

About Company

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.

Stock Peers

MKGAF

-6.5-3.38%

MERCK Kommanditgesellschaft auf Aktien$186.00 HKMPY

-0.87-1.69%

Hikma Pharmaceuticals PLC$50.66 SGIOF

Shionogi & Co., Ltd.$43.89 ESALF

Eisai Co., Ltd.$43.00 MKKGY

-0.85-2.24%

MERCK Kommanditgesellschaft auf Aktien$37.11 IPSEY

Ipsen S.A.$33.00 TKPHF

Takeda Pharmaceutical Company Limited$26.83 TEVJF

5.26+43.91%

Teva Pharmaceutical Industries Limited$17.24 APNHY

Aspen Pharmacare Holdings Limited$12.52 TAIPY

Taisho Pharmaceutical Holdings Co., Ltd.$12.00

Company Overview

Next Science Limited (OTC:NXSCF) closed at $0.01 USD, losing -$0.09 (-90.00%) from the previous close of $0.10. The stock is currently mid-range between its 52-week high and low $0.01 and $0.11. With a market capitalization of about $2.93 million, Next Science Limited is classified as a micro-cap and shows market-like volatility (beta ~1.22). Key stats such as the average daily volume over the past year has been around 1.93 thousand shares, trading with heavier-than-usual volume. Headquartered in Sydney, NSW, Next Science Limited operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia.

Technical Performance

Average 10-day trading volume of 80.00 thousand shares is significantly above the 3-month average of 21.64 thousand, indicating heightened recent market interest.

Valuation Metrics

Next Science Limited trades at a P/E ratio of -0.31, slightly below the S&P 500 average, with a price-to-sales ratio of 0.13 and a price-to-book ratio of -5.25 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.51, also below market averages.

Dividend & Fair Value

Next Science Limited last paid a dividend of 0.1 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.23. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Next Science Limited earnings surprise history is a mixed track record. The quarter that ended February 28, 2025, missed forecasts by -50.47%. The prior quarter beat by -64.84%. Over the last six quarters, Apple has recorded several small beats. These include 18.0% in February 27, 2024.

Financial & Profitability Overview

Over the trailing twelve months, Next Science generated $22.18M in revenue, or $0.09 per share. Gross margin was 73.20%, operating margin -69.92%, and net profit margin -73.36%. Returns are negative, with ROA at -90.90% and ROE at -126.91%.
On valuation metrics, Next Science trades at a P/E of -0.31, P/S of 0.13 and P/B of -5.25. The current ratio is 1.38 and quick ratio is 1.25. Operationally, the company’s inventory turnover is 6.28 and cash conversion cycle is -260.42 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -9.52, supported by a cash flow-to-debt ratio of -1.08.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Next Science posted revenue of $22.18M, down slightly from $11.71M in the prior quarter. Gross profit was $16.23M (margin 73.20%). Operating income was - $15.51M (margin -69.9%). Net income was- $16.27M (EPS - $0.07).
The company ended the quarter with $9.28M in cash and short-term investments, a total debt of $961.97K, and net debt of - $8.28M. Total assets were $17.90M, with equity of $12.82M. Financials further reflected weakness, with operating cash flow of - $15.06M, free cash flow of - $15.94M, and capital expenditures of - $884.47K.

Price Forecast & Outlook

Our AI price prediction model suggests that Next Science Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Next Science Limited trading at a premium to the broader market with a P/E of -0.31.

Frequently Asked Questions

What is the current Next Science Limited (NXSCF) stock price?

Next Science Limited (OTC: NXSCF) stock price is $0.01 in the last trading session. During the trading session, NXSCF stock reached the peak price of $0.06 while $0.01 was the lowest point it dropped to. The percentage change in NXSCF stock occurred in the recent session was -90% while the dollar amount for the price change in NXSCF stock was - $0.09.

NXSCF's industry and sector of operation?

The OTC listed NXSCF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Next Science Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NXSCF?

Mr. Jon Swanson
Chief Operating Officer
Ms. Judith Mitchell M.B.A.
MD, Chief Executive Officer & Executive Director
Mr. Michael Morello
Vice President of Sales
Dr. Matthew Franco Myntti
Founder & Chief Technology Officer
Ms. Jacqueline Butler CA (ICAEW)
Chief Financial Officer
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD
Company Sec.
Mr. Martyn Jacobs
Head of Investor Relations

How NXSCF did perform over past 52-week?

NXSCF's closing price is 52.76% higher than its 52-week low of $0.01 where as its distance from 52-week high of $0.11 is -58.01%.

How many employees does NXSCF have?

Number of NXSCF employees currently stands at 0.

Link for NXSCF official website?

Official Website of NXSCF is: https://www.nextscience.com

How do I contact NXSCF?

NXSCF could be contacted at phone 612 860 75126 and can also be accessed through its website. NXSCF operates from The Zenith Building, Tower A, Sydney, NSW 2067, Australia.

How many shares of NXSCF are traded daily?

NXSCF stock volume for the day was 40K shares. The average number of NXSCF shares traded daily for last 3 months was 1.93K.

What is the market cap of NXSCF currently?

The market value of NXSCF currently stands at $2.93M with its latest stock price at $0.01 and 292.63M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	0
Beta	1.24
Sales or Revenue	$22.18M
5Y Sales Change%	5.456%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

NXSCF Company Profile and Key Details

Next Science

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways

Company Overview

Valuation Metrics